Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress

Cardiovasc Res. 2011 Dec 1;92(3):375-84. doi: 10.1093/cvr/cvr232. Epub 2011 Aug 22.

Abstract

Aims: Mutations in the ALK1 gene, coding for an endothelial-specific receptor of the transforming growth factor-β superfamily, are the underlying cause of hereditary haemorrhagic telangiectasia type 2, but are also associated with familial pulmonary hypertension (PH). We assessed the lung vasculature of mice with a heterozygous deletion of Alk1 (Alk1(+/-)) for disease manifestations and levels of reactive O(2) species (ROS) implicated in both disorders.

Methods and results: Several signs of PH, including elevated right ventricular (RV) systolic pressure leading to RV hypertrophy, reduced vascular density, and increased thickness and outward remodelling of pulmonary arterioles, were observed in 8- to 18-week-old Alk1(+/-) mice relative to wild-type littermate controls. Higher ROS lung levels were also documented. At 3 weeks, Alk1(+/-) mice were indistinguishable from controls and were prevented from subsequently developing PH when treated with the anti-oxidant Tempol for 6 weeks, confirming a role for ROS in pathogenesis. Levels of NADPH oxidases and superoxide dismutases were higher in adults than newborns, but unchanged in Alk1(+/-) mice vs. controls. Prostaglandin metabolites were also normal in adult Alk1(+/-) lungs. In contrast, NO production was reduced, while endothelial NO synthase (eNOS)-dependent ROS production was increased in adult Alk1(+/-) mice. Pulmonary near resistance arteries from adult Alk1(+/-) mice showed less agonist-induced force and greater acetylcholine-induced relaxation; the later was normalized by catalase or Tempol treatment.

Conclusion: The increased pulmonary vascular remodelling in Alk1(+/-) mice leads to signs of PH and is associated with eNOS-dependent ROS production, which is preventable by anti-oxidant treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activin Receptors, Type I / deficiency*
  • Activin Receptors, Type I / genetics
  • Activin Receptors, Type II
  • Age Factors
  • Animals
  • Antihypertensive Agents / pharmacology
  • Antioxidants / pharmacology
  • Arterioles / metabolism
  • Arterioles / physiopathology
  • Blood Pressure* / drug effects
  • Catalase / metabolism
  • Cyclic N-Oxides / pharmacology
  • Dose-Response Relationship, Drug
  • Heterozygote
  • Hypertension, Pulmonary / genetics
  • Hypertension, Pulmonary / metabolism*
  • Hypertension, Pulmonary / pathology
  • Hypertension, Pulmonary / physiopathology
  • Hypertension, Pulmonary / prevention & control
  • Hypertrophy, Right Ventricular / genetics
  • Hypertrophy, Right Ventricular / metabolism
  • Hypertrophy, Right Ventricular / physiopathology
  • Lung / blood supply*
  • Mice
  • Mice, Knockout
  • NADPH Oxidases / metabolism
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / metabolism
  • Oxidative Stress* / drug effects
  • Prostaglandin-Endoperoxide Synthases / metabolism
  • Pulmonary Artery / metabolism*
  • Pulmonary Artery / pathology
  • Pulmonary Artery / physiopathology
  • Reactive Oxygen Species / metabolism*
  • Spin Labels
  • Superoxide Dismutase / metabolism
  • Vasodilation
  • Vasodilator Agents / pharmacology
  • Ventricular Function, Right
  • Ventricular Pressure

Substances

  • Antihypertensive Agents
  • Antioxidants
  • Cyclic N-Oxides
  • Reactive Oxygen Species
  • Spin Labels
  • Vasodilator Agents
  • Nitric Oxide
  • Catalase
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • Prostaglandin-Endoperoxide Synthases
  • Superoxide Dismutase
  • NADPH Oxidases
  • Activin Receptors, Type I
  • Activin Receptors, Type II
  • Acvrl1 protein, mouse
  • tempol